Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 20, 2008

Geospiza Acquires VizX Labs’ GeneSifter® Software

  • Geospiza expanded its product line with the acquisition of VizX Labs’ GeneSifter® Data Analysis software.

    GeneSifter is a web-based microarray analysis system that combines data management and analytical functions for microarray experiments. Along with GeneSifter, Geospiza will continue to use its FinchLab™ workflow management and data-analysis system in next-generation sequencing.

    “The integration of GeneSifter will accelerate expansion of our data-analysis capabilities and address the scientific community’s need for data management and analysis across multiple platforms. GeneSifter will expand our market by addressing the demand for sophisticated data analysis across microarray, capillary electrophoresis, and next-generation sequencing platforms,” says Rob Arnold, president of Geospiza.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »